English
简体中文
Total: £ 56.28
Published Date: 2026-04-16 | Pages: 132 | Tables: 128 | Pharma & Healthcare
The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 536 million by 2032, at a CAGR of 3.3% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
This report delivers a comprehensive overview of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine. The Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Segment by Type
Live vaccines
Inactivated vaccines
by Application
Government bidding
Market sales
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Overview
1.1 Product Definition
1.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Type
1.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Live vaccines
1.2.3 Inactivated vaccines
1.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Application
1.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Government bidding
1.3.3 Market sales
1.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue 2021–2032
1.4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales 2021–2032
1.4.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Competition by Manufacturers
2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Entry into the Industry
2.8 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Competitive Situation and Trends
2.8.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players Market Share by Revenue
2.8.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Scenario by Region
3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021–2032
3.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021–2026
3.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2027–2032
3.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region: 2021–2032
3.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region: 2021–2026
3.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region: 2027–2032
3.4 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Facts & Figures by Country
3.4.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021–2032)
3.4.3 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Facts & Figures by Country
3.5.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021–2032)
3.5.3 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2021–2032)
4.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2021–2026)
4.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2027–2032)
4.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (2021–2032)
4.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (2021–2026)
4.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (2027–2032)
4.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2021–2032)
5.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2021–2026)
5.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2027–2032)
5.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (2021–2032)
5.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (2021–2026)
5.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (2027–2032)
5.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 China Animal Husbandry Co., Ltd.
6.1.1 China Animal Husbandry Co., Ltd. Company Information
6.1.2 China Animal Husbandry Co., Ltd. Description and Business Overview
6.1.3 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.1.5 China Animal Husbandry Co., Ltd. Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Company Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 MSD Animal Health
6.3.1 MSD Animal Health Company Information
6.3.2 MSD Animal Health Description and Business Overview
6.3.3 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.3.5 MSD Animal Health Recent Developments/Updates
6.4 Sinopharm Animal Health
6.4.1 Sinopharm Animal Health Company Information
6.4.2 Sinopharm Animal Health Description and Business Overview
6.4.3 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.4.5 Sinopharm Animal Health Recent Developments/Updates
6.5 Ceva
6.5.1 Ceva Company Information
6.5.2 Ceva Description and Business Overview
6.5.3 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.5.5 Ceva Recent Developments/Updates
6.6 Ruipu Biological
6.6.1 Ruipu Biological Company Information
6.6.2 Ruipu Biological Description and Business Overview
6.6.3 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.6.5 Ruipu Biological Recent Developments/Updates
6.7 Qilu Animal Health
6.7.1 Qilu Animal Health Company Information
6.7.2 Qilu Animal Health Description and Business Overview
6.7.3 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.7.5 Qilu Animal Health Recent Developments/Updates
6.8 Dahuanong
6.8.1 Dahuanong Company Information
6.8.2 Dahuanong Description and Business Overview
6.8.3 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.8.5 Dahuanong Recent Developments/Updates
6.9 CAVAC
6.9.1 CAVAC Company Information
6.9.2 CAVAC Description and Business Overview
6.9.3 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.9.5 CAVAC Recent Developments/Updates
6.10 Komipharm
6.10.1 Komipharm Company Information
6.10.2 Komipharm Description and Business Overview
6.10.3 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.10.5 Komipharm Recent Developments/Updates
6.11 Agrovet
6.11.1 Agrovet Company Information
6.11.2 Agrovet Description and Business Overview
6.11.3 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.11.5 Agrovet Recent Developments/Updates
6.12 Bioveta
6.12.1 Bioveta Company Information
6.12.2 Bioveta Description and Business Overview
6.12.3 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.12.5 Bioveta Recent Developments/Updates
6.13 Jinyu
6.13.1 Jinyu Company Information
6.13.2 Jinyu Description and Business Overview
6.13.3 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.13.5 Jinyu Recent Developments/Updates
6.14 Phibro Animal Health
6.14.1 Phibro Animal Health Company Information
6.14.2 Phibro Animal Health Description and Business Overview
6.14.3 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.14.5 Phibro Animal Health Recent Developments/Updates
6.15 Tiankang
6.15.1 Tiankang Company Information
6.15.2 Tiankang Description and Business Overview
6.15.3 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.15.5 Tiankang Recent Developments/Updates
6.16 Zoetis
6.16.1 Zoetis Company Information
6.16.2 Zoetis Description and Business Overview
6.16.3 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.16.5 Zoetis Recent Developments/Updates
6.17 Yongshun Biological
6.17.1 Yongshun Biological Company Information
6.17.2 Yongshun Biological Description and Business Overview
6.17.3 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.17.5 Yongshun Biological Recent Developments/Updates
6.18 Pulike Biological
6.18.1 Pulike Biological Company Information
6.18.2 Pulike Biological Description and Business Overview
6.18.3 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
6.18.5 Pulike Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Chain Analysis
7.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Production Mode & Process Analysis
7.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales and Marketing
7.4.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Channels
7.4.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors
7.5 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customer Analysis
8 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Dynamics
8.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends
8.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers
8.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges
8.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (K Dose), 2021–2026
Table 18. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (K Dose), 2027–2032
Table 20. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2021–2026
Table 27. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2027–2032
Table 28. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2021–2026
Table 32. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2027–2032
Table 33. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2021–2026
Table 42. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2027–2032
Table 43. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Type (2021–2026)
Table 51. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Type (2027–2032)
Table 52. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Type (2021–2026)
Table 59. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Type (2027–2032)
Table 60. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Application (2021–2026)
Table 61. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Application (2027–2032)
Table 62. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Application (2021–2026)
Table 69. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Application (2027–2032)
Table 70. China Animal Husbandry Co., Ltd. Company Information
Table 71. China Animal Husbandry Co., Ltd. Description and Business Overview
Table 72. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 74. China Animal Husbandry Co., Ltd. Recent Developments/Updates
Table 75. Boehringer Ingelheim Company Information
Table 76. Boehringer Ingelheim Description and Business Overview
Table 77. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 79. Boehringer Ingelheim Recent Developments/Updates
Table 80. MSD Animal Health Company Information
Table 81. MSD Animal Health Description and Business Overview
Table 82. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 84. MSD Animal Health Recent Developments/Updates
Table 85. Sinopharm Animal Health Company Information
Table 86. Sinopharm Animal Health Description and Business Overview
Table 87. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 89. Sinopharm Animal Health Recent Developments/Updates
Table 90. Ceva Company Information
Table 91. Ceva Description and Business Overview
Table 92. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 94. Ceva Recent Developments/Updates
Table 95. Ruipu Biological Company Information
Table 96. Ruipu Biological Description and Business Overview
Table 97. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 99. Ruipu Biological Recent Developments/Updates
Table 100. Qilu Animal Health Company Information
Table 101. Qilu Animal Health Description and Business Overview
Table 102. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 104. Qilu Animal Health Recent Developments/Updates
Table 105. Dahuanong Company Information
Table 106. Dahuanong Description and Business Overview
Table 107. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 109. Dahuanong Recent Developments/Updates
Table 110. CAVAC Company Information
Table 111. CAVAC Description and Business Overview
Table 112. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 114. CAVAC Recent Developments/Updates
Table 115. Komipharm Company Information
Table 116. Komipharm Description and Business Overview
Table 117. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 118. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 119. Komipharm Recent Developments/Updates
Table 120. Agrovet Company Information
Table 121. Agrovet Description and Business Overview
Table 122. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 123. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 124. Agrovet Recent Developments/Updates
Table 125. Bioveta Company Information
Table 126. Bioveta Description and Business Overview
Table 127. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 128. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 129. Bioveta Recent Developments/Updates
Table 130. Jinyu Company Information
Table 131. Jinyu Description and Business Overview
Table 132. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 133. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 134. Jinyu Recent Developments/Updates
Table 135. Phibro Animal Health Company Information
Table 136. Phibro Animal Health Description and Business Overview
Table 137. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 138. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 139. Phibro Animal Health Recent Developments/Updates
Table 140. Tiankang Company Information
Table 141. Tiankang Description and Business Overview
Table 142. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 143. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 144. Tiankang Recent Developments/Updates
Table 145. Zoetis Company Information
Table 146. Zoetis Description and Business Overview
Table 147. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 148. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 149. Zoetis Recent Developments/Updates
Table 150. Yongshun Biological Company Information
Table 151. Yongshun Biological Description and Business Overview
Table 152. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 153. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 154. Yongshun Biological Recent Developments/Updates
Table 155. Pulike Biological Company Information
Table 156. Pulike Biological Description and Business Overview
Table 157. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 158. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 159. Pulike Biological Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List
Table 163. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers List
Table 164. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Trends
Table 165. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers
Table 166. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges
Table 167. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report
List of Figures
Figure 1. Product Picture of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine
Figure 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Type: 2025 & 2032
Figure 4. Live vaccines Product Picture
Figure 5. Inactivated vaccines Product Picture
Figure 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Application: 2025 & 2032
Figure 8. Government bidding
Figure 9. Market sales
Figure 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size (US$ Million), 2021–2032
Figure 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), 2021–2032
Figure 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price (US$/Dose), 2021–2032
Figure 14. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Report Years Considered
Figure 15. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Manufacturers in 2025
Figure 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players: Market Share by Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in 2025
Figure 18. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2021–2032)
Figure 21. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Country (2021–2032)
Figure 22. United States Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2021–2032)
Figure 25. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Country (2021–2032)
Figure 26. Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region (2021–2032)
Figure 33. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Indonesia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Thailand Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Malaysia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2021–2032)
Figure 43. Latin America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Type (2021–2032)
Figure 53. Global Revenue Market Share of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Type (2021–2032)
Figure 54. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Application (2021–2032)
Figure 56. Global Revenue Market Share of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Application (2021–2032)
Figure 57. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price (US$/Dose) by Application (2021–2032)
Figure 58. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
